Compare iShares MSCI China ETF (MCHI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Tango Therapeutics Inc. — how do they compare? iShares MSCI China ETF trades at $51.62 (market cap $5.91B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: iShares MSCI China ETF is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 65 Days and Tango Therapeutics Inc. for 0 Days on average.
| MCHI | TNGX | |
|---|---|---|
Market Cap | $5.91B | $3.75B |
Volume | 1,759,881 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $32.90 |
52-Week Low | $50.48 | $7.50 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI, the iShares MSCI China ETF, trades at $52.135, down 0.03% on the day with a bearish technical signal from moving averages. The ETF faces mixed sentiment amid China's economic challenges including industrial overcapacity and trade tensions, though corporate profits surged 26% in Q2 2026. Support and resistance cluster tightly around $52, indicating consolidation near current levels with neutral oscillator readings.
MCHI presents a valuation opportunity trading at a significant discount to historical averages versus US indices, but risks include China's regulatory uncertainty, global trade friction, and weak domestic consumption. The upcoming Trump-Xi summit on September 24 could provide catalysts through potential trade agreements, though protectionism concerns remain elevated for Chinese equity exposure.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
